Core Viewpoint - The stock market experienced fluctuations, particularly in the pharmaceutical sector, but the company's fundamentals and long-term industry trends remain positive [1][2] Group 1: Stock Performance - On June 17, the Hong Kong stock market indices showed a downward trend, with the Hang Seng Index falling by 0.34%, the Hang Seng China Enterprises Index down by 0.4%, and the Hang Seng Tech Index decreasing by 0.15% [1] - Pharmaceutical stocks generally retreated, with the company, Yaoshi Bang (9885.HK), dropping by 6.31% to close at 10.4 HKD [1] Group 2: Company Actions - In response to stock price volatility, the company has been actively repurchasing shares and increasing executive holdings to stabilize market expectations [1] - On June 17, the company repurchased 100,000 shares at a total cost of approximately 1.03 million HKD, averaging 10.31 HKD per share [1] - Since initiating a billion HKD repurchase plan on May 7, the company has repurchased a total of 5.53 million shares, with a total repurchase amount exceeding 43.34 million HKD [1] - Executive Director Chen Fei also increased his holdings by 100,000 shares on June 17, bringing the total to over 900,000 shares, reflecting management's confidence in the company's future [1] Group 3: Financial Performance - The company has released positive signals this year, achieving its first annual profit in 2024, with a net profit of 157 million HKD, representing a year-on-year increase of 20.1% [1] - High-margin business growth has accelerated, with the transaction scale of the brand's first-push business reaching 717 million HKD from January to April, a year-on-year increase of 108.1% [1] - The company's proprietary brand business reached 560 million HKD, showing a significant year-on-year growth of 532.3%, indicating the formation of new growth momentum [1] Group 4: Industry Trends - The company is adapting to future pharmacy industry upgrades by entering the fields of pharmaceutical robotics and AI models [2] - In June, the company formed a strategic partnership with leading collaborative robotics firm, Yuejiang Technology, to explore high-value-added business opportunities in new retail scenarios through pharmaceutical collaborative robots, AI models, and drug IoT technologies [2] - Industry experts believe that the recent decline in the pharmaceutical sector is more related to technical adjustments following profit-taking rather than direct impacts from industrial policies or significant fundamental changes [2]

Core Viewpoint - After a strong two-month rally, the stock price of Yaoshi Bang (9885.HK) consolidated between HKD 10-11 from June 9 to June 11, following a year-to-date increase of over 120% and a market capitalization exceeding HKD 7 billion [1][2] Group 1: Company Performance - Yaoshi Bang is expected to achieve a full turnaround to profitability in 2024, with a projected adjusted net profit of HKD 157 million, representing a year-on-year increase of 20.1% [1] - The company’s high-margin business has accelerated growth, with a transaction scale of HKD 717 million in its brand promotion business from January to April, marking a year-on-year increase of 108.1% [1] - The company’s fundamentals have shown significant improvement, validating its profit logic [1] Group 2: Strategic Initiatives - On June 3, Yaoshi Bang entered into a strategic partnership with leading collaborative robot company Yujian Technology, focusing on integrating pharmaceutical collaborative robots, AI models, and drug IoT technologies into new retail scenarios [1] - This initiative aims to explore high-value-added business opportunities targeting retail pharmacies [1] Group 3: Market Sentiment and Analyst Ratings - The company’s quality attributes have attracted significant institutional interest, with Changcheng Securities and Tianfeng Securities both issuing "Buy" ratings, while Xinda Securities is more optimistic, projecting a compound annual growth rate of 145% for net profit from 2024 to 2027 [2] - The management has demonstrated confidence through actions, including a billion-dollar buyback plan initiated in May 2025, with 5.435 million shares repurchased for over HKD 42.31 million from May 7 to June 11 [2] - The Hong Kong pharmaceutical sector remains active, with multiple policy benefits being released, indicating a potential new market rally [2]

Core Viewpoint - The strategic collaboration between Yaoshi Bang and Yujian focuses on the application of collaborative robots and AI products in the pharmaceutical sector, aiming to enhance the integration of robotics and the pharmaceutical industry [1] Group 1: Company Performance - Yaoshi Bang's stock price has surged, achieving a 52% increase in May and over 120% year-to-date, with a market capitalization exceeding HKD 7.5 billion [1][4] - The company reported a revenue of CNY 17.904 billion for 2024, a year-on-year increase of 5.5%, and a net profit of CNY 157 million, marking a 20.1% increase [3] - The company has successfully transitioned to profitability, indicating that previous investments in digitalization and supply chain optimization are yielding results [3] Group 2: Market Trends - The pharmaceutical sector in Hong Kong has shown strong performance, with the Hong Kong and A-share pharmaceutical indices rising over 35% and 43% respectively in 2025 [2] - The A-share pharmaceutical and biotechnology sector has also rebounded significantly, with a single-day trading volume of CNY 127.9 billion on June 3 [2] Group 3: Strategic Initiatives - Yaoshi Bang has initiated a share repurchase plan worth CNY 100 million, having repurchased 5.275 million shares for nearly HKD 40 million [4] - The company is entering the pharmaceutical robotics and AI model sector, collaborating with Yujian Technology to explore high-value business opportunities in retail pharmacies [3] Group 4: Analyst Perspectives - Analysts from Changcheng Securities project that Yaoshi Bang's revenue will reach CNY 20.327 billion, CNY 23.375 billion, and CNY 27.120 billion from 2025 to 2027, with corresponding net profits of CNY 124 million, CNY 379 million, and CNY 720 million [6] - Tianfeng Securities highlights that the company is entering a new phase of sustained profitability, marking a significant milestone in its growth trajectory [6] - Xinda Securities notes that the company has completed its major capital expenditure phase and is now positioned to enhance profitability through high-margin business initiatives [6]

Group 1 - The retail pharmacy industry is undergoing a deep adjustment period due to the dual pressures of deepening pharmaceutical reforms and sluggish consumer spending, with overall growth rates hitting a five-year low [1] - Major chain pharmacies are shifting from scale expansion to refined operations, focusing on "diversification," "new retail," and "specialization" to build differentiated competitive advantages [1] - The transformation of the pharmaceutical retail industry is showing three major trends: accelerated layout of dual-channel pharmacies, continuous expansion of DTP specialty pharmacies, and gradual improvement of the new retail health service ecosystem [1] Group 2 - The new retail model has a penetration rate of 82.8% among households for medicine preparation, temporary purchases, and flash delivery services [1] - Leading chain pharmacies like Dazhenglin and Yixintang have initiated full-chain service capability construction to seize new retail transformation opportunities [1] - Cost control and efficiency improvement have become trends, with most chain pharmacies slowing down store expansion and focusing on enhancing the operational efficiency of existing stores [1] Group 3 - The digital pharmacy leader Yaoshi Bang has recently announced a strategic partnership with global collaborative robot leader Yuejiang Technology to integrate technologies such as pharmaceutical collaborative robots, AI models, and drug IoT into new retail scenarios [2] - The application of these technologies aims to enhance efficiency in prescription review and medication services, as well as to achieve full-process drug traceability management [2] - Automation technology is expected to become the core infrastructure for the new retail transformation of pharmacies, marking a fundamental shift from labor-intensive to technology-driven operations [2]

Global Trade and Tariff Policy - The US has raised tariffs on imported steel and aluminum from 25% to 50%, causing concerns over global supply chain disruptions. The EU has threatened to implement countermeasures by July 14 if no agreement is reached, escalating trade tensions between the US and EU [3] - The Midwest aluminum premium surged by 54%, and steel futures rose over 8%, increasing cost pressures on downstream industries such as automotive and appliances [3] - Brazil and India have indicated they will take reciprocal measures or resort to the WTO if negotiations fail [3] US-China Trade Negotiations - The Trump administration has requested countries to submit their best trade proposals by June 4, or face the reinstatement of tariffs. China has responded by stating it will maintain communication based on the consensus from Geneva talks, with a potential extension of short-term tariff exemptions until the end of August [4] Federal Reserve and Interest Rate Policy - Federal Reserve officials have expressed caution regarding rapid interest rate cuts, emphasizing the need for more evidence of declining inflation. Current rates are seen as providing a solid foundation for economic conditions [5] - US factory orders fell by 3.7% month-on-month in April, marking the largest decline since January 2024, while job vacancies increased to 7.39 million, indicating a mixed picture of labor market resilience and cooling [6] - The market anticipates a 98% probability that the Federal Reserve will maintain interest rates in June, with the first rate cut potentially delayed until after July [7] Commodity Market - Oil prices have risen to a two-week high, with Brent crude increasing by 1.5% to $65.63 per barrel and US crude rising by 1.4% to $63.41 per barrel, influenced by ongoing Russia-Ukraine conflict and deadlock in the US-Iran nuclear deal [7] - Gold prices have faced downward pressure due to a strengthening dollar, with spot gold dropping nearly 1% to $3352.30 per ounce, while platinum and palladium prices rose by 0.9% and 2.1% respectively due to industrial demand [8] Stock Market Performance - US tech stocks led the market, with Nvidia rising nearly 3% to reclaim the title of the world's most valuable company, and Broadcom delivering record switch chip deliveries, contributing to the Nasdaq's first year-to-date gain [9] - In China, the Shanghai Composite Index rose by 0.43%, with the Shenzhen and ChiNext indices increasing by 0.16% and 0.48% respectively, supported by active trading in sectors such as innovative pharmaceuticals and robotics [10] Policy and Industry Highlights - A joint initiative by five departments has launched a campaign to promote the adoption of 124 models of new energy vehicles in rural areas, aiming to enhance charging infrastructure and vehicle-network interaction technology [11] - A collaboration between Yaoshi Bang and Yujian Technology is set to advance the development of pharmaceutical collaborative robots, with the medical robot market projected to exceed $373 million by 2028 [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 訂立戰略合作與業務部署協議 最新業務部署進展 此公告乃藥師幫股份有限公司（「本公司」，與 其 附 屬 公 司 合 稱「本集團」）自願作 出，以 告 知 其 股 東 及 潛 在 投 資 者 有 關 本 集 團 若 干 業 務 發 展 之 最 新 情 況。 本公司董事會（「董事會」）欣 然 宣 佈，於2025年6月3日，本 集 團 與 深 圳 市 越 疆 科 技 股份有限公司（其H股於香港聯合交易所有限公司主板上市；股份代號：2432.HK） （「越疆科技」）訂立戰略合作與業務部署協議（「戰略協議」），開 啟 緊 密 戰 略 合 作， 並 已 展 開 具 體 項 目 的 部 署。 有關合作背景介紹 本集團創立於20 ...